The Ridin’ For Kids Foundation has announced the child that will be benefiting from their 2025 fundraiser event.

The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis ... and the Children's Hospital of Philadelphia ...

The Ridin’ For Kids Foundation has announced the child ... including juvenile idiopathic arthritis, lupus, juvenile dermatomyositis and interstitial lung disease. She also has bone complications ...

In children and teenagers, treatment with zonisamide was associated with a significant reduction in the number of monthly ...

In a cohort of 21,655 children ages 6 to 8 years, the prevalence rate of refractive astigmatism of at least 1.0 diopter (D) ...

The COVID-19 pandemic has led to increased astigmatism in children, with prolonged screen time and less outdoor activity ...

If you experience persistent muscle weakness, fatigue and skin changes that don't seem to fade, it could be more than just ...

The first dose of the measles-mumps-rubella vaccine is given when children are 12 to 15 months old. Some doctors and parents ...

An 8-year-old northern Minnesota boy is one of the first in the country to receive a specific type of gene therapy treatment.

In pediatric patients aged 6 months to 5 years, the VE of mRNA-1273 against symptomatic infection was modest after a single dose and strong after a second dose.

Benjamin N. Ungar, MD, discussed characteristics of atopic dermatitis and how common AD is among children and adults in the U.S. He also talked about the diagnostic process and “the hope” to ...